Detail

Keywords

early-life determinants on developmental outcomes ; Immunological immaturity of the neonate; Infant, Extremely Premature; long- and short-term outcome of preterm infants; Microbiome Research; Neonatal Infections; Neonatal Neurology; Neonatal Nursing; Neonatology; Nosocomial Infections in the Neonatal Intensive Care Unit; Outcome of Extremely Premature Infants; Patient Safety; prevention of adverse impacts across infancy and childhood

Research group(s)

• Neonatal Infections and Immunology
  Head: Angelika Berger
  Members:
  Angelika Berger

Research interests

Innovative strategies in the management of extremely premature infants including less invasive surfactant administration (LISA) and individualized developmental care protocols (WEFIB, Wiener entwicklungsfördernde familienzentrierte individuelle Betreuung Frühgeborener), prevention of adverse impacts across infancy and childhood, long- and short-term outcome of preterm infants, early-life determinants on developmental outcomes, psychosocial well-being, diagnosis and treatment of infections of preterm infants, role of inflammation and the microbioime in the pathogenesis of preterm delivery and morbidities of preterm infants, perinatal infections including infections with Ureaplasma species during pregnancy and neonatal period.

Grants

• Cerebral Tissue Oxygen Saturation to Guide Oxygen Delivery (2017)
  Source of Funding: FWF (Austrian Science Fund), Programme Clinical Research (KLIF)
  Coordinator of the collaborative project
• The premature gut microbiome and the influence on neonatal immunity, brain development and white matter injury – The PreMiBraIn study (2017)
  Source of Funding: MedUni Vienna & University of Vienna, Inter-University Clusterproject between the University of Vienna and the Medical University of Vienna
  Principal Investigator
• When to intervene in posthemorrhagic hydrocephalus of preterm infants (2016)
  Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund 17189
  Principal Investigator
• Occupational Balance in parents of preterm infants (2014)
  Source of Funding: PHARMIG, Gemeinsame Gesundheitsziele Rahmen Pharmavertrag
  Principal Investigator
• Establishment of an Austrian Preterm Infant Follow-Up Registry (2013)
  Source of Funding: PHARMIG, Gemeinsame Gesundheitsziele Rahmen Pharmavertrag
  Principal Investigator
• Use of multiplex PCR for early diagnosis of neonatal sepsis (2011)
  Source of Funding: OeNB (Oesterreichische Nationalbank), Anniversary Fund 14277
  Principal Investigator

Selected publications

1. Jamnik, T. et al. (2022) “Next-generation biomonitoring of the early-life chemical exposome in neonatal and infant development,” Nature Communications. Edited by , 13(1). Available at: https://doi.org/10.1038/s41467-022-30204-y.
2. Seki, D. et al. (2021) “Aberrant gut-microbiota-immune-brain axis development in premature neonates with brain damage,” Cell Host & Microbe. Edited by , 29(10), pp. 1558–1572.e6. Available at: https://doi.org/10.1016/j.chom.2021.08.004.
3. Pristner, M. et al. (2024) “Neuroactive metabolites and bile acids are altered in extremely premature infants with brain injury,” Cell Reports Medicine. Edited by , 5(4), p. 101480. Available at: https://doi.org/10.1016/j.xcrm.2024.101480.
4. Rittenschober-Boehm, J. et al. (2023) “Intrauterine Detection of <i>Ureaplasma</i> Species after Vaginal Colonization in Pregnancy and Neonatal Outcome,” Neonatology. Edited by , 121(2), pp. 187–194. Available at: https://doi.org/10.1159/000534779.
5. Bellach, L. et al. (2022) “Packed red blood cell transfusion in preterm infants,” The Lancet Haematology. Edited by , 9(8), pp. e615–e626. Available at: https://doi.org/10.1016/s2352-3026(22)00207-1.